Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation

We present the case of a 53-year-old woman with prefibrotic stage primary myelofibrosis (PMF) who underwent cord blood transplantation. Nine years after transplantation, she relapsed, which was confirmed by a bone marrow examination. We decided to treat her using azacitidine. After three courses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumi, Masahiko, Kitahara, Mari, Shishido, Tsutomu, Kazumoto, Hiroko, Uematsu, Nozomu, Kirihara, Takehiko, Sato, Keijiro, Ueki, Toshimitsu, Hiroshima, Yuki, Kobayashi, Hikaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691036/
https://www.ncbi.nlm.nih.gov/pubmed/32641650
http://dx.doi.org/10.2169/internalmedicine.4863-20
_version_ 1783614203098038272
author Sumi, Masahiko
Kitahara, Mari
Shishido, Tsutomu
Kazumoto, Hiroko
Uematsu, Nozomu
Kirihara, Takehiko
Sato, Keijiro
Ueki, Toshimitsu
Hiroshima, Yuki
Kobayashi, Hikaru
author_facet Sumi, Masahiko
Kitahara, Mari
Shishido, Tsutomu
Kazumoto, Hiroko
Uematsu, Nozomu
Kirihara, Takehiko
Sato, Keijiro
Ueki, Toshimitsu
Hiroshima, Yuki
Kobayashi, Hikaru
author_sort Sumi, Masahiko
collection PubMed
description We present the case of a 53-year-old woman with prefibrotic stage primary myelofibrosis (PMF) who underwent cord blood transplantation. Nine years after transplantation, she relapsed, which was confirmed by a bone marrow examination. We decided to treat her using azacitidine. After three courses of azacitidine, a partial cytogenetic response was confirmed. Azacitidine maintenance therapy successfully maintained a low level of recipient-origin peripheral blood cells with a stable hematological condition. Azacitidine may therefore be a promising therapeutic option for PMF patients who relapse after allogeneic stem cell transplantation.
format Online
Article
Text
id pubmed-7691036
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-76910362020-12-03 Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation Sumi, Masahiko Kitahara, Mari Shishido, Tsutomu Kazumoto, Hiroko Uematsu, Nozomu Kirihara, Takehiko Sato, Keijiro Ueki, Toshimitsu Hiroshima, Yuki Kobayashi, Hikaru Intern Med Case Report We present the case of a 53-year-old woman with prefibrotic stage primary myelofibrosis (PMF) who underwent cord blood transplantation. Nine years after transplantation, she relapsed, which was confirmed by a bone marrow examination. We decided to treat her using azacitidine. After three courses of azacitidine, a partial cytogenetic response was confirmed. Azacitidine maintenance therapy successfully maintained a low level of recipient-origin peripheral blood cells with a stable hematological condition. Azacitidine may therefore be a promising therapeutic option for PMF patients who relapse after allogeneic stem cell transplantation. The Japanese Society of Internal Medicine 2020-07-07 2020-11-01 /pmc/articles/PMC7691036/ /pubmed/32641650 http://dx.doi.org/10.2169/internalmedicine.4863-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sumi, Masahiko
Kitahara, Mari
Shishido, Tsutomu
Kazumoto, Hiroko
Uematsu, Nozomu
Kirihara, Takehiko
Sato, Keijiro
Ueki, Toshimitsu
Hiroshima, Yuki
Kobayashi, Hikaru
Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title_full Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title_fullStr Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title_full_unstemmed Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title_short Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
title_sort salvage therapy using azacitidine for relapsed primary myelofibrosis after cord blood transplantation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691036/
https://www.ncbi.nlm.nih.gov/pubmed/32641650
http://dx.doi.org/10.2169/internalmedicine.4863-20
work_keys_str_mv AT sumimasahiko salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT kitaharamari salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT shishidotsutomu salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT kazumotohiroko salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT uematsunozomu salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT kiriharatakehiko salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT satokeijiro salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT uekitoshimitsu salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT hiroshimayuki salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation
AT kobayashihikaru salvagetherapyusingazacitidineforrelapsedprimarymyelofibrosisaftercordbloodtransplantation

Ejemplares similares